Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16)

Andreas Du Bois; Anne Floquet; Jae Weon Kim; Jörn Rau; Jose Maria Del Campo; Michael Friedlander; Sandro Pignata; Keiichi Fujiwara; Ignace Vergote; Nicoletta Colombo; Mansoor Raza Mirza; Bradley J. Monk; Pauline Wimberger; Isabelle Ray-Coquard; Rongyu Zang; Ivan Diaz-Padilla; Klaus H. Baumann; Jae Hoon Kim; Philipp Harter; on behalf of an Intergroup consortium

doi:10.1200/jco.2013.31.15_suppl.lba5503

Back

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16)

Journal article

Peer reviewed

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16)

Andreas Du Bois, Anne Floquet, Jae Weon Kim, Jörn Rau, Jose Maria Del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, …

Journal of clinical oncology, Vol.31(15_suppl), pp.LBA5503-LBA5503

05/20/2013

DOI: https://doi.org/10.1200/jco.2013.31.15_suppl.lba5503

Abstract

Abstract only LBA5503 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Metrics

6 Record Views

Details

Title: Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16)
Creators: Andreas Du Bois - Kliniken Essen-Mitte
Anne Floquet - Institut Bergonié
Jae Weon Kim - Seoul National University
Jörn Rau - Philipps University of Marburg
Jose Maria Del Campo - Vall d’Hebron Institute of Oncology, Barcelona, Spain
Michael Friedlander - Prince of Wales Hospital
Sandro Pignata - National Cancer Institute of Naples, Naples, Italy
Keiichi Fujiwara - Saitama Medical University
Ignace Vergote - Universitair Ziekenhuis Leuven
Nicoletta Colombo - University of Milano-Bicocca
Mansoor Raza Mirza - Copenhagen University Hospital
Bradley J. Monk - Creighton University
Pauline Wimberger - University of Duisburg-Essen
Isabelle Ray-Coquard - Centre Léon Bérard
Rongyu Zang - Fudan University
Ivan Diaz-Padilla - Centro Oncológico de Galicia
Klaus H. Baumann - Philipps University of Marburg
Jae Hoon Kim - Yonsei University
Philipp Harter - Kliniken Essen-Mitte
on behalf of an Intergroup consortium
Publication Details: Journal of clinical oncology, Vol.31(15_suppl), pp.LBA5503-LBA5503
Identifiers: 991005968881902656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16)

Abstract

Related links

Metrics

Details